Abstract
Background
Invasive aspergillosis (IA) is most commonly caused by the morphospecies Aspergillus fumigatus. However, genetic-based methods indicate that organisms phenotypically identified as A. fumigatus actually constitute a mold complex, designated Aspergillus section fumigati subgenus fumigati.
Methods
Multilocus sequencing and analysis was performed on fungi identified as A. fumigatus from the clinical culture collection maintained at the National Institutes of Health from 2000 through 2008, with a focus on the internal transcribed spacer 1 and 2 regions of ribosomal DNA (rDNA), b-tubulin, and rodlet A genes. We reviewed the medical records, radiology, and histopathology of corresponding patients. To confirm identification of Neosartorya udagawae isolates, mating studies were performed with reference strains. Antifungal susceptibility testing was performed by broth microdilution and read at 48 hours.
Results
Thirty-six cases of infection attributed to A. fumigatus were identified; 4 were caused by N. udagawae (3 in patients with chronic granulomatous disease and 1 in a patient with myelodysplastic syndrome). Disease due to N. udagawae was chronic, with a median duration of 35 weeks, compared with a median duration of 5.5 weeks for patients with chronic granulomatous disease who had infection due to A. fumigatus sensu stricto (P < .05, Mann-Whitney U test). Infection spread across anatomical planes in a contiguous manner and was refractory to standard therapy. Two of the 4 patients died. N. udagawae demonstrated relatively higher minimum inhibitory concentrations to various agents, compared with those demonstrated by contemporary A. fumigatus sensu stricto isolates.
Conclusions
To our knowledge, this is the first report documenting infection due to N. udagawae. Clinical manifestations were distinct from those of typical IA. Fumigati-mimetics with inherent potential for antifungal resistance are agents of IA. Genetic identification of molds should be considered for unusual or refractory IA.
Invasive aspergillosis (IA) affects 5%–20% of patients with hematological malignancies and transplants [1–3]. Overall mortality rates range from 30% to 60% [4–7]. Most mold-attributable deaths occur within the first 6 weeks of treatment [8]. Among primary immunodeficiencies, chronic granulomatous disease (CGD) patients are uniquely susceptible to IA, with 25%–35% of these patients affected [9, 10]. Therefore, CGD provides an opportunity to study this infection within the context of a fixed immunological deficit.
Refractory IA, which has been defined as disease progression or failure to clinically improve after <7 days of standard therapy [11, 12], may be a function of underlying disease, concomitant iatrogenic immunosuppression, or pharmacokinetics. Pathogen-related factors are poorly understood. Drug susceptibility is inferred from speciation. Most isolates of Aspergillus fumigatus are considered to be sensitive to amphotericin B (AmB), extended-spectrum triazoles, and caspofungin [12].
IA is most commonly caused by A. fumigatus, a morphospecies identification based on phenotype of colonies and spore-bearing structures. However, organisms previously recognized as A. fumigatus now constitute a complex that is designated Aspergillus section fumigati subgenus fumigati. Within this group are asexual members (anamorphs, termed Aspergillus), some of which may also have sexual forms (teleomorphs, termed Neosartorya). Anamorphic human pathogens include A. fumigatus sensu stricto and Aspergillus lentulus, while pathogenic teleomorphs include Neosartorya pseudofischeri, Neosartorya fischeri, and Neosartorya hiratsukae. Although these organisms display the characteristic microscopic morphology of A. fumigatus in vitro, they may behave differently. Thus, the clinical relevance of subspeciation remains unclear.
Neosartorya udagawae, which resembles A. fumigatus, was originally identified from Brazilian soil [13]. Its anamorph, Aspergillus udagawae, has been identified among clinical culture collections, although disease was not documented [14]. We describe N. udagawae that caused disease distinct from typical IA.
METHODS
Case identification
The National Institutes of Health clinical microbiology database for the period 2000–2008 was reviewed for molds that fulfilled the following criteria: (1) the mold was a filamentous fungus resembling or reported as A. fumigatus, (2) the source of the isolate was a significant clinical specimen (e.g., tissue and sterile sources), and (3) sequence-based identification (see below) was performed on the isolate. The respective patients were identified and their medical records, computed tomographs, and histopathology were reviewed. The estimated duration of IA was defined as the time from documentation of first symptom of infection (or first radiographic evidence if asymptomatic) to death from infection or control of disease. Control of disease was defined as the earliest date of radiologic improvement or stabilization associated with resolution of clinical symptoms [15].
Morphological identification
Isolates were identified on the basis of colony features and morphology under light microscopy by means of routine clinical mycology laboratory media and incubation conditions.
Genetic identification
Isolates were identified by multilocus sequence analysis of the internal transcribed spacer 1 and 2 regions flanking 5.8S ribosomal DNA (rDNA) (ITS1-5.8S-ITS2), (partial) b-tubulin gene (benA), and (partial) rodlet A gene (rodA), as described elsewhere [16–18]. Briefly, each isolate was subcultured onto Sabouraud dextrose agar at 37°C for 5 days. Mycelial DNA was extracted using the UltraClean Microbial DNA Isolation kit, according to manufacturer’s modifications for molds (MoBio Laboratories). Polymerase chain reaction was followed by amplicon purification with the Microcon YM-100 centrifugation filter device (Millipore). Sequencing was performed on the 3100 sequencer (Applied Biosystems), analyzed using Lasergene software (DNASTAR), and compared with GenBank sequences by means of nucleotide-nucleotide Basic Local Alignment Search Tool (BLASTn). Multiple-sequence alignment was performed with CLUSTAL W, and percent similarity was calculated.
Strains
The type strains of heterothallic N. udagawae from Centraalbureau voor Schimmelcultures (CBS; 114217 and 114218) are environmental strains that represent 2 opposite mating types. The 4 clinical isolates and the reference strains were grown on malt or oatmeal agar plates at room temperature for 7 days. Conidia were harvested in phosphate-buffered saline with polysorbate surfactant (Tween) at a concentration of 0.01% and washed with ultrapure water. The A. fumigatus clinical strain, B-5233, was cultured as described elsewhere [19]. For morphological studies, conidia were inoculated onto thin layers of malt agar, incubated for 3–7 days at 37°C, and visualized by light microscopy with lactophenol cotton blue.
Mating studies
To confirm genetic-based identification, mating studies were performed between each clinical isolate and the reference strains on oatmeal agar incubated at 25°C in the dark for <6 weeks [20].
Antifungal susceptibility testing
Broth microdilution was performed at the Fungus Testing Laboratory, University of Texas Health Sciences Center, according to guidelines from the Clinical and Laboratory Standards Institute [21]. Minimum inhibitory concentrations (MICs) at 48 hours were reported for AmB, itraconazole, voriconazole, posaconazole, and terbinafine. Minimum effective concentrations at 48 hours were reported for caspofungin and micafungin.
CLINICAL CASES
Patient 1
A 27-year-old man with X-linked CGD presented with cough and hemoptysis. A left lower-lobe nodule yielded a mold morphologically identified as A. fumigatus. AmB and voriconazole led to some symptomatic improvement. AmB treatment was discontinued. He was discharged with a regimen of voriconazole, but cough and hemoptysis recurred.
He had had recurrent cases of pneumonia with Aspergillus (no species documented), each apparently successfully treated with AmB. When he was 16 years old, progressive disease with Aspergillus nidulans required partial lobectomy, thoracoplasty, and vertebral resection with rod placement. In his 20s, he developed cases of pneumonia with Paecilomyces species, Pseudallescheria boydii, and Burkholderia cepacia complex; all resolved with therapy.
Computed tomography at admission showed multiple left lower-lung nodules. Aspirate yielded A. fumigatus (subsequently identified as N. udagawae). Treatment was modified to voriconazole and caspofungin. Progression over 2 weeks prompted a change to posaconazole. Two weeks later, new and increasing foci compelled a change to AmB. After 2 weeks, a mixed radiological response resulted in the addition of caspofungin. Clinical and radiological stability was achieved 5.5 months after disease onset. One month later, improvement in the consolidations continued.
Patient 2
A 36-year-old woman with CGD presented with nonproductive cough and dyspnea. Computed tomography demonstrated lingular infiltrate with a small cavity. Biopsy was not diagnostic. Broad-spectrum antibiotics and itraconazole (400 mg intravenous daily) were started. One week later, she developed mediastinal lymphadenopathy with left pleuralbased thickening. During the ensuing 6 weeks, she slowly became better without significant radiologic improvement. She was discharged with a regimen of itraconazole (400 mg orally daily). After 2.5 months, the dosage of itraconazole was reduced by half for nausea. Two weeks later, productive cough, worsened lingular consolidation, scattered nodules, and persistent mediastinal lymphadenopathy prompted lung biopsies that yielded A. fumigatus (subsequently N. udagawae). Voriconazole was initiated, but elevated hepatic transaminases prompted a change to posaconazole 10 days later. After 7 weeks, there was significant clinical improvement, normalization of inflammatory markers, and radiologic regression. She completed 7 months of posaconazole without complications.
Patient 3
A 33-year-old man with an undefined immu nodeficiency presented with fever and pancytopenia. Disseminated histoplasmosis failed to improve after 3 weeks of liposomal AmB, and he was transferred to the National Institutes of Health. Further investigation showed diffuse pulmonary interstitial thickening, infiltrates in the left pulmonary apex and right lower lobe, and disseminated Mycobacterium avium complex. Posaconazole, antimycobacterial therapy, and interferong eventually resolved both infections. During his illness, bone marrow analyses showed a myelodysplastic syndrome associated with monosomy 7. While in the hospital and receiving posaconazole, he developed worsening left apical consolidation. Biopsy grew A. fumigatus (subsequently N. udagawae). Treatment with voriconazole and caspofungin was begun. During the ensuing 11 months, despite several modifications in antimycotics, the apical consolidation expanded, involving the pleura, lingula, fissure, and left lower lobe, accompanied by mediastinal and hilar lymphadenopathy. The right lung demonstrated fluctuating improvement in the lower-lobe consolidation but developed new lesions involving the major fissure, right middle lobe, and apex and a recalcitrant pleural effusion. One year into hospitalization, new fevers with worsening infiltrates led to isolation of N. udagawae from bronchoalveolar lavage. Thyroid lesions were observed. Neurological deficits and bilateral cerebral hypodensities led to a biopsy which showed acutely branching septated hyphae, although cultures yielded no organism. AmB, terbinafine, and flucytosine were added. Steroids were required for brain edema. The patient expired 5 days later. At autopsy, septated bulbous hyphae were identified diffusely in the lungs (figure 1A) with multiple pleural adhesions, in the left ventricular and septal myocardium with fibrinous pericardium along the tricuspid valve, in both thyroid lobes, and in the brain.
Figure 1.
A, Histopathology of infected lung (patient 3); B, Cytology of liver abscess (patient 4) with Gomori methenamine silver stain demonstrating branching septated hyphae with varicose and/or bulbous hyphal forms.
Patient 4
A 29-year-old man with X-linked CGD was referred for progressive aspergillosis. He had had recurrent cases of pneumonia with a mold identified as A. fumigatus over a protracted course, despite treatment with itraconazole and AmB, wedge resection of the right upper lobe with resection of the first and second ribs at age 15, repeat wedge resection at age 17, and completion of the right upper lobectomy at age 21. At age 23, right-sided pneumonia with involvement of the chest wall yielded A. fumigatus from bronchoalveolar lavage and lung biopsy. Because of presumed AmB-related renal failure, treatment with caspofungin was initiated, with temporary improvement. During the ensuing 3 months, he had intermittent hemoptysis, worsening right lung infiltrates, right paratracheal lymphadenopathy, nodules in the azygoesophageal recess and left upper lobe, and left lower-lobe infiltrate. Voriconazole and caspofungin led to minimal improvement. At age 27, a new right infiltrate yielded a nonsporulating hyaline septated mold on bronchoalveolar lavage. An 11 × 8–cm abscess necessitated through the right anterior chest wall. Debridement of necrotic pectoralis muscle yielded a similar mold. A combination of voriconazole and caspofungin was reinitiated. At age 28, while he was receiving therapy, there was worsening drainage from the chest wall and new left upper-lobe consolidation. Cultures of exudate and biopsies grew a nonsporulating mold identified as A. fumigatus by a commercial sequencing kit that targeted partial D2 (28S rDNA) region.
Three months later, evaluation for dyspnea and fever showed pulmonary infiltrates and hepatic abscesses (figure 2). Liver biopsy yielded A. fumigatus. Treatment with voriconazole and caspofungin was continued, and the patient was transferred to the National Institutes of Health. The abscesses were drained percutaneously (figure 1B). A. fumigatus (subsequently N. udagawae) was isolated. Antifungals were changed to posaconazole and micafungin. Chest wall ulcer and bronchoscopies showed septated hyphae. Despite additional AmB and terbinafine, the patient died. Autopsy found fibrosis and chronic granulomatous reaction in the right lung, miliary abscesses in the left lung with a septated bulbous hyaline mold, bilateral pleural adhesions, adhesions between liver and diaphragm, fungal abscesses in the hepatic subcapsular and subphrenic spaces without microscopic evidence of diaphragmatic hyphal invasion, sterile abscess in splenic hilum, and mesenteric lymphadenopathy.
Figure 2.
Serial computed tomographs that demonstrate contiguous involvement across anatomical planes. A, Computed chest tomograph demonstrating diffuse nodular infiltrates in the left lung and nodules in the right lung, along with ulceration in the right anterior chest wall. B, Multiple hypodense lesions are visualized in the liver. Neosartorya udagawae was isolated from the lungs, chest wall ulcer, and liver.
RESULTS
From 2000 through 2008, 36 cases of invasive A. fumigatus that fulfilled inclusion criteria were identified at the National Institutes of Health: 15 patients had CGD, 5 had leukemia and/or lymphoma, 5 had cancer, 3 had autosomal-dominant hyperimmunoglobulin-E syndrome, and 8 had other illnesses. Sources were pulmonary and/or pleural in 33 cases and extrathoracic in 3 cases.
There were 4 infections with N. udagawae that was identified by multilocus sequence analysis, which accounted for 11% of our IA cases (table 1). Three patients had CGD, and 1 patient had an undefined immunodeficiency with myelodysplastic syndrome. The estimated duration of infection in these patients ranged from 26 to 728 weeks (mean, 206.1 weeks; median, 35.25 weeks). Since the majority of N. udagawae cases involved CGD patients, a comparator group was identified consisting of all CGD cases within the same time period from which A. fumigatus sensu stricto by multilocus sequencing was isolated (n = 12). The estimated duration of infection in this latter group ranged from 1.5 to 10 weeks (mean and median, 5.3 weeks; P < .05, Mann-Whitney U test). In all cases involving N. udagawae, there was radiological evidence of progressive disease across anatomical planes, with expansion or development of new infiltrates involving adjacent pulmonary lobes, pleurae, chest wall, and/or mediastinal structures (lymph nodes or vasculature). In patients 3 and 4, there was subsequent involvement of the contralateral lung and other organs. All patients underwent at least 3 modifications in antifungal regimens because of refractory disease.
Table 1.
Characteristics of patients and clinical features of disease due to Neosartorya udagawae.
Patient identifier |
Age in years, sex |
Year | Underlying disease | Primary site of infection |
Subsequent sites of involvement | Estimated duration of illness |
Outcome |
---|---|---|---|---|---|---|---|
1 | 27, M | 2004 | CGD (gp91phox) | Left lower lobe | Expansion of primary infiltrate with multiple new areas in left lung; subcarinal lymphadenopathy | <26 weeks | Survived |
2 | 36, F | 2002 | CGD (p47phox) | Lingula | Worsening consolidation in lingula and left lower lobe; left pleural-based thickening; mediastinal lymphadenopathy | <26.5 weeks | Survived |
3 | 33, M | 2006 | Myelodysplastic syndrome | Left upper lobe | Expansion of primary infiltrate, left pleura, lingula, left lower lobe; mediastinal and hilar lymphadenopathy; right lung; myocardium and valves; thyroid; brain | <44 weeks | Deceased |
4 | 29, M | 2008 | CGD (gp91phox) | Right upper lobe | Progression of primary lesion; mediastinal lymphadenopathy; left lung; right anterior chest wall; liver; mesenteric lymphadenopathy | Possibly 14 years | Deceased |
NOTE. CGD, chronic granulomatous disease.
Although conidial structures in the 4 strains of N. udagawae were similar to those of A. fumigatus (figure 3), the growth rate and colony morphology were different. All N. udagawae strains grew significantly slower than A. fumigatus sensu stricto at 37°C, and they produced cottony colonies with abundant fluffy aerial hyphae and poor conidiation, as opposed to velvety colonies of A. fumigatus with heavy conidiation. Such findings, however, cannot be considered specific for N. udagawae. Sequence analysis of the ITS1-5.8S-ITS2 rDNA region and benA and rodA genes from the isolates allowed their definitive identification. Although clinical isolates of N. udagawae may have poor mating capacity [14], 1 of our isolates mated successfully with type strain CBS-114218, producing abundant cleistothecia at the junction where the 2 strains met (figure 4), confirming that our isolate was indeed N. udagawae. Although the other 3 isolates failed to mate, multilocus sequencing results for these latter 3 were nearly identical to the former clinical isolate, confirming that all isolates were N. udagawae.
Figure 3.
Light microscopy with lactophenol cotton-blue staining of culture of Neosartorya udagawae (from patient 2, A; from patient 4, C) demonstrating morphologic features similar to those of Aspergillus fumigatus sensu stricto (B).
Figure 4.
Mating study of clinical isolate (A, top and bottom quadrants) with mating-type reference strains of Neosartorya udagawae (A, left and right quadrants). Production of cleistothecia (B) confirmed multilocus sequence identification of N. udagawae
Antifungal susceptibility results demonstrated that N. udagawae was relatively resistant to AmB, itraconazole, and voriconazole, compared with A. fumigatus sensu stricto (table 2).
Table 2.
Antifungal susceptibility of Neosartorya udagawae clinical isolates.
Source of isolate | AmB | Itraconazole | Voriconazole | Posaconazole | Caspofungin | Micafungin | Terbinafine |
---|---|---|---|---|---|---|---|
Patient 1 | 1 | 1 | 2 | 0.25 | 1 | −0.015 | 0.25 |
Patient 2 | 2 | 1 | 2 | 0.25 | 0.25 | −0.015 | 0.5 |
Patient 3 | 2 | 4 | 116 | 0.5 | 0.5 | −0.015 | 0.5 |
Patient 4 | 0.5–1 | 1 | 1–4 | 0.5 | 0.25–0.5 | −0.015 | 0.5–1 |
Aspergillus fumigatus sensu strictoa | 0.25 | 0.06–0.5 | 0.25–0.5 | 0.03–0.125 | 0.06–0.125 | ND | ND |
NOTE. Data are minimum inhibitory concentrations or, for the echinocandins, minimal effective concentrations, expressed as mg/L. AmB, amphotericin B; ND, not determined.
Composite result of 3 contemporary isolates from patients with chronic granulomatous disease who were undergoing selective antifungal testing.
DISCUSSION
Survival rates for IA range from 40% to 70%; these low rates imply many cases of refractory disease, but the exact frequency is difficult to estimate. Host factors clearly impact clinical manifestations and outcome. However, pathogen phylogeny and accompanying differences in mold biology are emerging as important. Consequently, the heterogeneity of what is called A. fumigatus may account for some of the clinical variability of IA, including refractory disease.
Disease with N. udagawae in our 4 patients was chronic and progressive, features which characterize refractory IA [22, 23]. IA outcomes are usually decided within the first 6 weeks of therapy [8]. Likewise, in our contemporaneous CGD cohort with IA due to A. fumigatus sensu stricto, response to therapy typically occurred by <5.5 weeks. Disease with N. udagawae was protracted (median, 35.25 weeks).
The pattern of spread was also distinct. IA associated with neutropenia primarily involves the lungs with a propensity for angioinvasion and hematogenous dissemination [24]. IA due to A. fumigatus sensu stricto in CGD patients was typically localized to the lungs; hematogenous dissemination is uncommon [25, 26]. IA due to A. nidulans demonstrates a propensity for local extension and dissemination [25]. IA due to N. udagawae was characterized by a primary pulmonary focus, with subsequent progression to ipsilateral adjacent structures. If the IA was not controlled, subsequent radiological involvement of the contralateral lung and viscera occurred. Because this pattern was seen in both those with CGD and one patient with myelodysplastic syndrome, we suspect that this propensity for contiguous spread is inherent to the mold and not to the specific underlying disease.
N. udagawae appears relatively refractory to therapy. In all patients, multiple modifications in treatment were made. Most A. fumigatus isolates are highly susceptible to AmB and voriconazole, with MICs from −0.5 to 1 mg/L [27–29]. N. udagawae clearly differs in resistance (table 2). When optimal growth is achieved in vitro for susceptibility testing, MICs to AmB and voriconazole are typically elevated. Although no consensus interpretive criteria for antifungal susceptibility results are established, this elevation suggests that N. udagawae is more resistant in vitro to these first-line antifungals than are typical A. fumigatus clinical isolates, and this difference in resistance mirrors the in vivo phenomenon. Detailed microbiological characterization of N. udagawae will be published elsewhere.
N. udagawae caused 4 (11%) of 36 IA cases at our center over an 8-year period. It morphologically resembles A. fumigatus [13], and the molds from all 4 patients were initially identified as such. Poor in vitro sporulation, lack of microscopic structures that distinguish between A. fumigatus and N. udagawae, and poor mating capacity of clinical N. udagawae isolates impede timely and accurate identification. The mold from patient 4 was additionally identified as A. fumigatus via partial sequencing of the 28S rDNA by commercial kit. However, multilocus DNA sequence analysis clearly distinguished these 4 isolates of N. udagawae from A. fumigatus sensu stricto. A retrospective review of medical records unambiguously demonstrated that the clinical course for these cases was distinct from typical IA. This series illustrates the clinical relevance of Aspergillus taxonomy and the potential for this methodology to study the clinical impact of the infecting mold subspecies. Invasive infections with fumigati-mimetics have been previously reported in patients with various underlying diseases, involving N. pseudofischeri (anamorph, Aspergillus thermomutatus), N. fischeri (anamorph, Aspergillus fischerianus), and N. hiratsukae (anamorph, Aspergillus hiratsukae) (table 3). The estimated median duration of illness for these 3 organisms was 12.75, 3.3, and 12 weeks, respectively. The corresponding mortality rates were 2 (33%) of 6 patients with N. pseudofischeri and 2 (67%) of 3 patients with N. fischeri. A. lentulus was isolated from hematology transplant recipients, all of whom died despite receiving recommended therapy for IA [17]. Most fumigati-mimetic primary isolates produced fluffy white colonies because of abundant aerial hyphae with poor sporulation at room temperature and were presumptively identified as Aspergillus species or A. fumigatus. Accurate identification was predominantly by DNA analyses. Together with our series, these reports demonstrate the importance of molds that resemble A. fumigatus as distinct causes of IA and the difficulties in their identification.
Table 3.
Review of Neosartorya species infections in the literature.
Reference | Patient’s age, sex |
Underlying disease | Infecting organism | Site of infection | Estimated duration of illness | Treatment | Outcome |
---|---|---|---|---|---|---|---|
Gerber et al. 1973 [30] | 57 years, M | NR | A. fischeri var. spinosus [N pseudofischeri]a | Lung | 8 months (3 months while receiving therapy) | AmB | Survived |
Coriglione et al. 1990 [31] | 62 years, M | NR | N. fischeri var. fischeri (Wehmer) Malloch and Cain [N. pseudofischeri]a | Eye (keratitis progressing to endophthalmitis) | 9 days | Oral and intravenous itraconazole | Enucleation |
Summerbell et al. 1992 [32] | 2 months, M | Tetralogy of Fallot requiring cardiac surgery | N. fischeri var. spinosa [N. pseudofischeri]a | Pulmonic valve endocarditis, pericardial graft, and myocardial necrosis | <7.5 weeks | AmB | Deceased |
Padhye et al. 1994 [33] | 77 years, M | History of silicosis and tuberculosis | N. pseudofischeri | Osteomyelitis of second and third lumbar vertebrae | <4.5 months | NR | NR |
Lonial et al. 1997 [34] | 48 years, M | Leukemia requiring allogeneic BMT, complicated by GVHD and multiple cases of bacteremia | N. fischeri | Skin (trunk, shoulders, arms), progressing to brain; on autopsy, multiple organs affected (heart, lungs, liver, spleen, thyroid, skin, brain) | 32 days | AmB (625 mg total), changed to liposomal AmB because of progression of infection | Deceased |
Chim et al. 1998 [35] | 56 years, F | Multiple myeloma with chemotherapy-induced neutropenia | A. fischeri [N. fischeri] | Lung (BAL) | NR | AmB (and acyclovir for herpes simplex virus pneumonia) | Survived |
Gori et al. 1998 [36] | 42 years, M | Hepatitis C–associated cirrhosis requiring liver transplant, then retransplant, complicated by renal failure | N. fischeri | Lung (BAL), with dissemination to brain | 2 weeks | Liposomal AmB and 5-fluorocytosine | Deceased |
Guarro et al. 2002 [37] | 75 years, F | NR | N. hiratsukae | Multifocal brain abscesses | <3 months | AmB, complicated by hypokalemia; changed to itraconazole; multiple surgical drainages | Initial clinical improveement; subsequently deceased from multiorgan failure, cause unidentified |
Matsumoto et al. 2002 [38] | 8 years, F | Peritoneal dialysis for renal failure from focal segmental glomerulosclerosis | N. pseudofischeri | Serosa of jejunum and peritoneal ascitic fluid | 210 days | AmB, complicated by infusional reactions; changed to liposomal AmB; maintenance therapy with itraconazole | Protracted hospital course; repeated episodes of jejunal perforation; survived |
Jarv et al. 2004 [39] | 17 years, M | Hodgkin disease requiring second line chemotherapy for induction | N. pseudofischeri | Initially identified in blood; subsequent lung involvement (CT halo sign and positive serum galactomannan) | 32 days | AmB for 16 days, with improvement, followed by itraconazole | Infection resolved; relapse of Hodgkin disease |
Balajee et al. 2005 [40] | NR | Leukemia requiring stem cell transplant | N. pseudofischeri | Ear biopsy (invasive otitis) | NR | AmB lipid complex, followed by voriconazole and caspofungin | Infection successfully treated; subsequently deceased from progressive leukemia |
NOTE. BAL, bronchoalveolar lavage; BMT, bone marrow transplant; CT, computed tomograph; GVHD, graft-versus-host disease; NR, none reported
Reidentified by Peterson as N. pseudofischeri on the basis of scanning electron microscopy of ascospores and on DNA complementarity [33].
Antifungal susceptibility data for the fumigati-mimetics are emerging. N. pseudofischeri displays higher MICs to voriconazole and possibly to AmB, compared with A. fumigatus sensu stricto [41]. A. lentulus demonstrates in vitro resistance to numerous antifungal agents [42]. A. udagawae from clinical specimens has higher MICs to AmB and voriconazole, although no clinical context was provided [14]. Thus, fumigati-mimetic molds tend to demonstrate in vitro resistance to antifungal agents routinely used in the treatment of IA, potentially contributing to refractory disease.
In this retrospective study, we parsimoniously estimated that the duration of illness dated from the recovery of previous isolates identified as A. fumigatus at the referring institutions and presumed these to be in fact N. udagawae, given the strong phenotypic resemblance between the 2 organisms. Because some of these isolates significantly predate patient evaluation at the National Institutes of Health, we were unable to successfully retrieve them to confirm identity. As a corollary, it is possible that the eventual isolation of N. udagawae from these patients was the result of selective pressure during successful treatment of previous episodes with A. fumigatus sensu stricto. However, the fact that N. udagawae was repeatedly isolated, over a prolonged period, from various specimens recovered from patients during hospitalization at our institution confirms that this mold can cause chronic infection.
N. udagawae and other fumigati-mimetics may account for a significant portion of refractory IA. Both deaths in our series were directly attributable to N. udagawae: 1 patient with CGD and 1 patient with myelodysplastic syndrome. Therefore, severe disease due to N. udagawae is not confined to a single immunodeficiency, unlike A. nidulans that is essentially restricted to CGD. The search for fumigati-mimetics in unusual or refractory IA is underway.
In summary, infection with N. udagawae can cause disease distinct from typical IA, being chronic and refractory with a propensity to spread across anatomic planes. Multilocus DNA sequence analysis permitted accurate identification. These observations have important implications for fungal identification in the clinical laboratory and in future studies of IA.
Acknowledgments
Financial support. Canadian Institutes of Health Research fellowship (to D.C.V.); National Institutes of Health Supplemental Visiting fellowship (to D.C.V.); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (N01CO-12400); and National Cancer Institute, National Institutes of Health (HHSN261200800001E).
Footnotes
Potential conflicts of interest. All authors: no conflicts.
References
- 1.Bow EJ. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol. 2008;140:133–152. doi: 10.1111/j.1365-2141.2007.06906.x. [DOI] [PubMed] [Google Scholar]
- 2.Iversen M, Burton C, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879–886. doi: 10.1007/s10096-007-0376-3. [DOI] [PubMed] [Google Scholar]
- 3.Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258–266. doi: 10.1016/s1053-2498(02)00477-1. [DOI] [PubMed] [Google Scholar]
- 4.Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. doi: 10.1056/NEJMoa020191. [DOI] [PubMed] [Google Scholar]
- 5.Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial) Clin Infect Dis. 2007;44:1289–1297. doi: 10.1086/514341. [DOI] [PubMed] [Google Scholar]
- 6.Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176–1184. doi: 10.1086/592255. [DOI] [PubMed] [Google Scholar]
- 7.Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67:1567–1601. doi: 10.2165/00003495-200767110-00004. [DOI] [PubMed] [Google Scholar]
- 8.Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer. 2008;112:2309–2312. doi: 10.1002/cncr.23441. [DOI] [PubMed] [Google Scholar]
- 9.Winkelstein JA, Marino MC, Johnston RB, Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155–169. doi: 10.1097/00005792-200005000-00003. [DOI] [PubMed] [Google Scholar]
- 10.Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152:211–218. doi: 10.1111/j.1365-2249.2008.03644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–1571. doi: 10.1086/423381. [DOI] [PubMed] [Google Scholar]
- 12.Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360. doi: 10.1086/525258. [DOI] [PubMed] [Google Scholar]
- 13.Horie Y, Miyaji M, Nishimura K, Franco M, Coelho K. New and interesting species of Neosartorya from Brazilian soil. Mycoscience. 1995;36:199–204. [Google Scholar]
- 14.Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell. 2006;5:1705–1712. doi: 10.1128/EC.00162-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis. 2008;47:674–683. doi: 10.1086/590566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA sequences for phylogenetics. In: Innis MA, et al., editors. PCR protocols: a guide to methods and applications. New York: Academic Press; 1990. pp. 315–322. [Google Scholar]
- 17.Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus . Eukaryot Cell. 2005;4:625–632. doi: 10.1128/EC.4.3.625-632.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Balajee SA, Houbraken J, Verweij PE, et al. Aspergillus species identification in the clinical setting. Stud Mycol. 2007;59:39–46. doi: 10.3114/sim.2007.59.05. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Sugui JA, Kim HS, Zarember KA, et al. Genes differentially expressed in conidia and hyphae of Aspergillus fumigatus upon exposure to human neutrophils. PLoS ONE. 2008;3:e2655. doi: 10.1371/journal.pone.0002655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kwon-Chung KJ, Kim SJ. A second heterothallic Aspergillus . Mycologia. 1974;56:628–638. [PubMed] [Google Scholar]
- 21.Clinical and Laboratory Standards Institute (CLSI) CLSI document M38-A2. 2nd ed. Wayne, PA: CLSI; 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. [Google Scholar]
- 22.Caillot D, Couaillier J-F, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253–259. doi: 10.1200/JCO.2001.19.1.253. [DOI] [PubMed] [Google Scholar]
- 23.Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV Immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol. 2006;187:404–413. doi: 10.2214/AJR.05.0513. [DOI] [PubMed] [Google Scholar]
- 24.Perea S, Patterson TF. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect. 2002;17:99–105. doi: 10.1053/srin.2002.33443. [DOI] [PubMed] [Google Scholar]
- 25.Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998;77:345–354. doi: 10.1097/00005792-199809000-00004. [DOI] [PubMed] [Google Scholar]
- 26.Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45:673–681. doi: 10.1086/520985. [DOI] [PubMed] [Google Scholar]
- 27.Araujo R, Coutinho I, Espinel-Ingroff A. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption. J Antimicrob Chemother. 2008;62:1277–1280. doi: 10.1093/jac/dkn415. [DOI] [PubMed] [Google Scholar]
- 28.Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol. 2008;46:2568–2572. doi: 10.1128/JCM.00535-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61:616–620. doi: 10.1093/jac/dkm518. [DOI] [PubMed] [Google Scholar]
- 30.Gerber J, Chomicki J, Brandsberg JW, Jones R, Hammerman KJ. Pulmonary aspergillosis caused by Aspergillus fischeri var. spinosus: report of a case and value of serologic studies. Am J Clin Pathol. 1973;60:861–866. doi: 10.1093/ajcp/60.6.861. [DOI] [PubMed] [Google Scholar]
- 31.Coriglione G, Stella G, Gafa L, et al. Neosartorya fischeri var fischeri (Wehmer) Malloch and Cain 1972 (anamorph: Aspergillus fischerianus Samson and Gams 1985) as a cause of mycotic keratitis. Eur J Epidemiol. 1990;6:382–385. doi: 10.1007/BF00151712. [DOI] [PubMed] [Google Scholar]
- 32.Summerbell RC, de Repentigny L, Chartrand C, St Germain G. Graftrelated endocarditis caused by Neosartorya fischeri var. spinosa. J Clin Microbiol. 1992;30:1580–1582. doi: 10.1128/jcm.30.6.1580-1582.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Padhye AA, Godfrey JH, Chandler FW, Peterson SW. Osteomyelitis caused by Neosartorya pseudofischeri . J Clin Microbiol. 1994;32:2832–2836. doi: 10.1128/jcm.32.11.2832-2836.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lonial S, Williams L, Carrum G, Ostrowski M, McCarthy J. Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient. Bone Marrow Transplant. 1997;19:753–755. doi: 10.1038/sj.bmt.1700715. [DOI] [PubMed] [Google Scholar]
- 35.Chim CS, Ho PL, Yuen KY. Simultaneous Aspergillus fischeri and Herpes simplex pneumonia in a patient with multiple myeloma. Scand J Infect Dis. 1998;30:190–191. doi: 10.1080/003655498750003627. [DOI] [PubMed] [Google Scholar]
- 36.Gori S, Pellegrini G, Filipponi F, et al. Pulmonary aspergillosis caused by Neosartorya fischeri (Aspergillus fischerianus) in a liver transplant recipient. J Mycol Med. 1998;8:105–107. [Google Scholar]
- 37.Guarro J, Kallas EG, Godoy P, et al. Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil. Emerg Infect Dis. 2002;8:989–991. doi: 10.3201/eid0809.020073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Matsumoto N, Shiraga H, Takahashi K, Kikuchi K, Ito K. Successful treatment of Aspergillus peritonitis in a peritoneal dialysis patient. Pediatric Nephrology. 2002;17:243–245. doi: 10.1007/s00467-002-0821-6. [DOI] [PubMed] [Google Scholar]
- 39.Jarv H, Lehtmaa J, Summerbell RC, Hoekstra ES, Samson RA, Naaber P. Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary aspergillosis. J Clin Microbiol. 2004;42:925–928. doi: 10.1128/JCM.42.2.925-928.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus . J Clin Microbiol. 2005;43:5996–5999. doi: 10.1128/JCM.43.12.5996-5999.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez Tudela JL. Aspergillus section fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52:1244–1251. doi: 10.1128/AAC.00942-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother. 2004;48:1197–1203. doi: 10.1128/AAC.48.4.1197-1203.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]